Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase 1 study of NBI-1070770 in healthy adults and patients with major depressive disorder
NL-OMON61131Phase 1Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NBI-1070770 in major depressive disorder (MDD) (4 arms), sponsored by Neurocrine Biosciences. Primary endpoint: Frequency of treatment-emergent adverse events. Started Aug 2022; status: completed.
02
Drugs
NBI-1070770
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NL-OMON61131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61131.